Gilead sees FY23 adjusted EPS $6.60-$7.00, consensus $6.73

Sees FY23 total product sales $26B-$26.5B, consensus $25.76B. Sees Total product sales, excluding Veklury, between $24.0 billion and $24.5 billion. Total Veklury sales of approximately $2.0 billion are expected to be highly variable, depending on the frequency and severity of surges, and guidance will continue to be updated on a quarterly basis as necessary.